ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1514736
This article is part of the Research TopicNutrition in Cancer Patients Undergoing Targeted Therapy: From Mechanisms to Clinical PracticeView all 3 articles
Efficacy prediction of systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) in breast cancer patients and their variations after Neoadjuvant chemotherapy
Provisionally accepted
- 1Affiliated Tumor Hospital of Nantong University, Nantong Jiangsu, China
- 2Nantong Liangchun Hospital of Traditional Chinese Medicine, Nantong, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The purpose of this study was to evaluate the predictive values of systemic immune-inflammatory index (SII), prognostic nutrition index (PNI), change of SII (ΔSII), change of PNI (ΔPNI) and ΔPNI-ΔSII score in patients with neoadjuvant chemotherapy for breast cancer.We enrolled in a retrospective study involving 72 patients with breast cancer between February 2020 and January 2022. All patients had clinical features of axillary lymph node metastasis and received neoadjuvant therapy. PNI and SII were detected by hematology before and after treatment. Chi-square test was used to compare the clinicopathological and experimental parameters among all groups.Logistic regression analysis was used to evaluate the prognostic value of each factor.The prognosis was evaluated and 18 patients (25%) achieved pathological complete response (pCR) after neoadjuvant therapy. The pCR rate of breast cancer patients was significantly correlated with ER, PR, HER-2, molecular subsets, tumor size, vascular invasion, nerve invasion, N stage, clinical stage and chemotherapy regimen. Low ΔPNI, high ΔSII and higher ΔPNI-ΔSII score values had better prediction of therapeutic effect, especially the ΔPNI-ΔSII score.In breast cancer patients receiving neoadjuvant chemotherapy, ΔPNI-ΔSII score is an effective predictor of efficacy, which helps to identify high-risk groups and evaluate efficacy.
Keywords: breast cancer, systemic immune-inflammation index, Prognostic nutritional index, Neoadjuvant chemotherapy, prognosis
Received: 07 Nov 2024; Accepted: 21 Apr 2025.
Copyright: © 2025 Ni, Qi, Jin, Xu, Li, Song and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xunlei Zhang, Affiliated Tumor Hospital of Nantong University, Nantong Jiangsu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.